TANGO THERAPEUTICS INC (TNGX)

Company Profile

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2020-09-03. The firm leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The firm's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).

Company Info

TANGO THERAPEUTICS INC

201 Brookline Avenue, Suite 901

Boston MASSACHUSETTS

P: 18573204900

CEO: Aaron I. Davis

Employees: 140

Website: https://www.tangotx.com/